You are here

P&T News

September 26

Medication is indicated for the treatment of seven inflammatory diseases
It is the first biologic that targets interleukin-12 and interleukin-23 cytokines active in the disease
The potential blockbuster was granted breakthrough therapy status in 2014
Drug previously approved for cryopyrin-associated periodic syndromes and active systemic juvenile idiopathic arthritis
Studies also will address HIV prevention among at-risk groups

September 23

Another facet of national opioid epidemic?
Treatment improves progression-free survival versus standard chemotherapy
Scientists demystify popular MS drug
Subcutaneous nanoparticles may help control autoimmune disorders

September 22

Participants could seek less-costly mix of patients, authors say
New study comes amid price-hike furor
Sales staff downplayed drug’s addictive potential, court documents claim
Lantus gets the boot for diabetes

September 21

Agency official overrules staff’s protests
Doctors dissatisfied with regulatory/paperwork burdens
Proposals are “unnecessary and ill-advised,” expert says
Once-daily canagliflozin/metformin combo lowers glucose
Anorectic drug is administered three times daily

Pages